Last reviewed 2026-04-20 · How we verify

Thiaton (TIQUIZIUM)

Phase 2 active Small molecule

Thiaton (generic name: TIQUIZIUM) is a tiquizium drug. It is currently in Phase 2 development for Abdominal pain.

Thiaton works by interacting with a specific molecular target to reduce pain signals in the body.

Thiaton, also known as Tiquizium, is a small molecule drug in the tiquizium class. It is used to treat abdominal pain, but its exact target is unknown. The commercial status of Thiaton is unclear, and it is not known whether it is patented or available as a generic medication. Further information on its pharmacokinetics, such as half-life and bioavailability, is also lacking. As a result, key safety considerations and potential side effects are not well established.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	TIQUIZIUM
Drug class	tiquizium
Modality	Small molecule
Therapeutic area	Pain
Phase	Phase 2

Mechanism of action

Imagine your body has a messaging system that sends pain signals to your brain. Thiaton helps block these pain messages, making you feel less pain. This is done by binding to a specific protein that is involved in sending these pain signals.

Approved indications

Abdominal pain

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Thiaton CI brief — competitive landscape report
Thiaton updates RSS · CI watch RSS

Frequently asked questions about Thiaton

What is Thiaton?

Thiaton (TIQUIZIUM) is a tiquizium drug, indicated for Abdominal pain.

How does Thiaton work?

Thiaton works by interacting with a specific molecular target to reduce pain signals in the body.

What is Thiaton used for?

Thiaton is indicated for Abdominal pain.

What is the generic name of Thiaton?

TIQUIZIUM is the generic (nonproprietary) name of Thiaton.

What drug class is Thiaton in?

Thiaton belongs to the tiquizium class. See all tiquizium drugs at /class/tiquizium.

What development phase is Thiaton in?

Thiaton is in Phase 2.

Drug class: All tiquizium drugs
Therapeutic area: All drugs in Pain
Indication: Drugs for Abdominal pain

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing